SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
- Author
- Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
- Published
- Sat 11 Nov 2023
- Episode Link
- https://audioboom.com/posts/8401847
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
